American College of Gastroenterology

Evidence-Based GI: An ACG Publication and Podcast

Health EN ↓ Odcinki: 146

A new monthly publication from the American College of Gastroenterology, Evidence-Based GI (EBGI) uses evidence-based methods to create abstracts and explain study results of new and important articles in the field of gastroenterology and hepatology. Listen as editors of EBGI discuss the articles they review and how the recommendations can be applied to your practice.

Koniecznie odwiedź stronę podcastu i wesprzyj twórcę: gi.org

Autor

American College of Gastroenterology

Kategoria

Health

Strona podcastu

gi.org

Ostatni odcinek

29 kwi 2026

Gdzie słuchać?

Podcasty w aplikacji Replaio Radio Już wkrótce

Podcasty trafią do aplikacji już wkrótce. Zainstaluj teraz i jako pierwszy zobacz nowe podejście do podcastów

Pobierz z Google Play Zainstaluj za darmo Android prawie 10 mln pobrań · ocena 4,8 iOS niedługo

Odcinki

Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone 22.02.2023
Early Colonoscopy for Acute Lower GI Bleeding Usually Is Not the Answer 22.02.2023
Endoscopic Sleeve Gastroplasty Is Effective for Patients with Obesity Who MERIT Intervention 22.02.2023
Dupilumab, an IgG4 Monoclonal Antibody, for Eosinophilic Esophagitis: Revising the Treatment Paradigm 22.02.2023
ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM Trial 03.02.2023
When It’s Not Acid Reflux: Managing PPI-Resistant GERD Patients Based on Bravo Results 25.01.2023
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy 25.01.2023
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy 25.01.2023
Ozanimod, a Selective Selective Sphingosine-1-Phosphatase Receptor Modulator, for Moderate-Severe Ulcerative Colitis: Re-Thinking the Top-Down Treatment Algorithm for UC 13.12.2022
Continuing Anti-TNF Agents past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes 13.12.2022
NSAID Use and the Risk of IBD Exacerbations: Fact or Fiction 13.12.2022
RBX2660, a Donor Stool Product for Fecal Microbiota Transplant, Decreases Recurrent Clostridioides difficile Infection: The First FDA-Approved Live Biotherapeutic Product 13.12.2022
Reinvestigating the Lack of Association Between Proton Pump Inhibitor Use and Mortality by Accounting for Reverse Causation 11.11.2022
Vonoprazan, a Potassium-Channel Acid Blocker, is Superior to Lansoprazole for Managing Erosive Esophagitis 11.11.2022
ICYMI: Surgery is Superior to Medical Therapy for PPI-Refractory Heartburn in the “Right” Patients 11.11.2022
Acute pancreatitis: Need IV fluid resuscitation but avoid a WATERFALL! 18.10.2022
High Adenoma Detection Rate Decreases Post-Colonoscopy CRC in FIT-Based Screening Program: Quality Matters! 18.10.2022
Colonoscopy Reduces CRC Incidence and CRC-Related Mortality…. If You Get It! 18.10.2022
Upadacitinib, a Selective JAK1 Inhibitor, for Moderate-Severe Ulcerative Colitis: Adjusting the Top-Down Treatment Algorithm for UC 18.10.2022
Time to Increase Adenoma Detection Rate Benchmarks for Screening Colonoscopies 21.09.2022
Achieve IBD Remission Before Pregnancy: PIANO Registry Data Shows Adverse Perinatal Outcomes For Infants Associated with IBD Flares and Steroid Use; and Continue Thiopurines and Anti-TNF Agents If Your IBD Patient Becomes Pregnant 21.09.2022
ICYMI-Pantoprazole Prophylaxis Does Not Reduce 90-day Mortality and Clinically Significant Adverse Events in ICU Patients 21.09.2022
Prophylactic Rifaximin Decreases Post-TIPS Hepatic Encephalopathy 11.08.2022
Tiny Polyps-It’s OK to Remove Polyps equal or less than 3mm with Large Biopsy Forceps 11.08.2022
ADR Isn’t the Only Game in Town: Proximal Serrated Lesion Detection Rates Predicts Interval Cancer Risk 11.08.2022

Słuchaj podcastu Evidence-Based GI: An ACG Publication and Podcast w Replaio

Radio i podcasty w jednej aplikacji - za darmo, bez zakładania konta. Zainstaluj już dziś i nie przegap premiery

Pobierz z Google Play

Replaio nie jest wydawcą podcastów; nazwy audycji, okładki i audio należą do ich autorów i są rozpowszechniane przez publiczne kanały RSS